Publication: Spirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPS
No. of Pages/File Size
World Journal of Microbiology and Biotechnology. Vol.31, No.2 (2014), 391-398
Jirayut Euanorasetr, Bungonsiri Intra, Phayungsak Mongkol, Surang Chankhamhaengdecha, Patoomratana Tuchinda, Mihoko Mori, Kazuro Shiomi, Takuya Nihira, Watanalai Panbangred (2014). Spirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPS. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/33433.
Spirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPS
© 2014, Springer Science+Business Media Dordrecht. The rare actinomycetes strain 2EPS was isolated from soil and analysis of cultural, morphological characteristics, diaminopimelic acid content of its cell wall, and 16S rRNA gene sequence indicates that 2EPS belongs to genus Actinomadura. In addition, neighbor-joining phylogenetic tree also confirmed the relationships of this strain to other members of Actinomadura. A butanol extract with antibacterial activity was purified by reversed-phase chromatography to obtain three bioactive compounds, designated as compounds 1, 2 and 3. The structures of these compounds were determined using spectroscopic analysis (1H-NMR and13C-NMR) and mass spectrometric analysis (HR-TOF-MS). Compounds 1–3 were identified and found to be the same as those included in the Japanese patent number JP 09227587 for spirotetronate antibiotics and are BE-45722A (1), BE-45722B (2) and BE-45722C (3), respectively. All compounds were active against Gram-positive bacteria (Staphylococcus aureus ATCC 25923, Bacillus cereus ATCC 14579, and B. subtilis ATCC 6633) with low MIC values between 0.08 and 5.0 µg/ml. Moreover, both 1 and 3 also exhibited strong activity, with similar MIC values, against Clostridiumperfringens S107 at 0.63 µg/ml and C. difficile 630 at 0.08 µg/ml. These results suggest the identified spirotetronate compounds may have potential in the treatment of Clostridium infections. Overall, this analysis demonstrates that rare actinomycetes are a promising source for discovery of antimicrobial compounds.